ICLR · ICON plc
$185.27
-0.09% last session
End-of-day data · close of 2026-10-23
Market cap
$14B
Enterprise value
$17B
Trailing P/E
195.0
Forward P/E
15.7
Dividend yield
0.0%
Beta
1.24
Avg volume
1M
Employees
40K
Daily Change %
-0.09%
5 Days Change
8.96%
10 Days Change
12.83%
30 Days Change
13.14%
60 Days Change
6.89%
Month to Day Change
14.57%
Year to Day Change
1.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ICLR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-18
Latest call per bank · past 12 months
Citigroup
Neutral$175
-5.5% vs priceBarclays
Equal-Weight$175
-5.5% vs priceRBC Capital
Outperform$185
-0.1% vs priceJP Morgan
Neutral$155
-16.3% vs priceBank of America
Underperform$150
-19.0% vs priceJefferies
Buy$135
-27.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-18 | Citigroup | Maintains | Neutral | $180 → $175 |
| 2026-07-31 | Citigroup | Maintains | Neutral | $165 → $180 |
| 2026-07-31 | Truist Securities | Reiterates | Buy | $207 → $209 |
| 2026-06-30 | Truist Securities | Upgrade | Hold → Buy | $159 → $207 |
| 2026-06-26 | Mizuho | Maintains | Outperform | $180 → $190 |
| 2026-06-25 | Citigroup | Maintains | Neutral | $140 → $165 |
| 2026-06-25 | BMO Capital | Maintains | Outperform | $160 → $187 |
| 2026-06-25 | Barclays | Maintains | Equal-Weight | $160 → $175 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 65 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 9.8% above the 50-day MA ($168.74).
- bullish: Price vs 200-day MA: Trading 27.5% above the 200-day MA ($145.35).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+2.20) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($80.08) and high ($202.92).
ICLR Price Chart
Loading chart for ICLR…
Fundamentals
About ICON plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.